Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia

Study Overview
=================
Brief Summary
-----------------
This is a retrospective, monocentric study involving 50 patients with pancreatic neuroendocrine neoplasia resected between January 2008 and June 2020 at Paoli Calmettes Institute. The primary objective of the study is to evaluate the grade concordance rate, based on Ki67 obtained on the pre-operative micro-biopsy and the surgical specimen. Based on the histology slides obtained in the course of the treatment, several Ki67 recounts will be performed on pre-operative tumor micro-biopsies and on tumors resected after surgery: a manual count (on photo printed in the hotspot area according to World Health Organization (WHO) 2017 recommendations, by an expert pathologist and a junior pathologist. Automated counting using specific software based on artificial intelligence (Qpath software). On the other hand, clinical, surgical and anatomopathological data will be collected in order to follow the patient evolution.

Official Title
-----------------
Comparison of the Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia Between Preoperative Micro-biopsies and Surgical Specimens

Conditions
-----------------
Neuroendocrine Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with resection of pancreatic neuroendocrine neoplasia by surgery at Paoli Calmettes Institute between January 2008 and June 2020 Patients who had a pre-surgical evaluation of Ki67 on micro-biopsy equipment obtained by echo-endoscopy. Exclusion Criteria: Patient with a mixed tumor of the pancreas. Patient with a pancreas tumor composed of several nodules of similar size without a main mass and for which it is not possible to determine the biopsied nodule during echo-endoscopy. Initial micro-biopsy in a private pathology laboratory Initial subechoendoscopic puncture cytology only (Ki67 not possible) No initial micro-biopsy and surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ki67 Grade | Evaluation by a pathologist by manual counting according to WHO 2017 recommendations | on pre-operative micro-biopsies | 
| Ki67 Grade | Evaluation by a pathologist by manual counting according to WHO 2017 recommendations | on surgical specimens | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Ki67 positive cells on total counted cells | Evaluation by a pathologist by manual counting according to WHO 2017 recommendations | on preoperative micro-biopsies | 
| Percentage of Ki67 positive cells on total counted cells | Evaluation by a pathologist by manual counting according to WHO 2017 recommendations | on surgical specimens | 
| Percentage of Ki67 positive cells on total counted cells | Evaluation by digital pathology before and after machine learning | on preoperative micro-biopsies | 
| Percentage of Ki67 positive cells on total counted cells | Evaluation by digital pathology before and after machine learning | on surgical specimens | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pancreatic neuroendocrine tumor, Ki67, artificial intelligency